Elaine Siegfried, MD – St. Louis University and Heather Brandling-Bennett – University of Washington
Methotrexate is a time-honored drug, used for over 50 years for a wide variety of indications, across all routes of administration. Literature suggests there is currently substantial variation in how methotrexate is used to manage pediatric inflammatory diseases. In this era of expensive biologic and small molecule medications, methotrexate remains an effective, inexpensive, and readily available therapeutic option that pediatric subspecialists (including pediatric dermatologists) should feel comfortable prescribing for their patients. This project will use a consensus development conference method to create evidence-based and consensus-derived guidelines for use of methotrexate in pediatric patients with inflammatory skin disease. Our aim is to create robust, enduring guidelines to facilitate effective and safe use of methotrexate to treat pediatric skin and other inflammatory diseases that require systemic therapy.
This study was funded as a 2018 PeDRA Team Grant and is currently underway.